Johnson & Johnson (NYSE: JNJ) has a price-to-earnings ratio that is above its average at 28.67x. The stock has a 36-month beta value of 0.48. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 3 as “overweight,” 13 as “hold,” and 0 as “sell.”
The public float for JNJ is 2.41B, and at present, short sellers hold a 1.03% of that float. On March 31, 2025, the average trading volume of JNJ was 9.00M shares.
JNJ) stock’s latest price update
The stock of Johnson & Johnson (NYSE: JNJ) has increased by 1.52 when compared to last closing price of 163.71. Despite this, the company has experienced a 1.78% gain in its stock price over the last five trading sessions. zacks.com reported 2025-03-31 that Study investigators expect that J&J’s combo drug can extend overall survival by at least a year over the current standard of care in certain NSCLC patients.
JNJ’s Market Performance
JNJ’s stock has risen by 1.78% in the past week, with a monthly rise of 0.71% and a quarterly rise of 14.16%. The volatility ratio for the week is 1.45% while the volatility levels for the last 30 days are 1.49% for Johnson & Johnson The simple moving average for the past 20 days is 1.31% for JNJ’s stock, with a 6.32% simple moving average for the past 200 days.
Analysts’ Opinion of JNJ
Many brokerage firms have already submitted their reports for JNJ stocks, with BofA Securities repeating the rating for JNJ by listing it as a “Neutral.” The predicted price for JNJ in the upcoming period, according to BofA Securities is $166 based on the research report published on December 10, 2024 of the previous year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see JNJ reach a price target of $190. The rating they have provided for JNJ stocks is “Outperform” according to the report published on November 15th, 2024.
Daiwa Securities gave a rating of “Neutral” to JNJ, setting the target price at $150 in the report published on July 23rd of the previous year.
JNJ Trading at 4.61% from the 50-Day Moving Average
After a stumble in the market that brought JNJ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.23% of loss for the given period.
Volatility was left at 1.49%, however, over the last 30 days, the volatility rate increased by 1.45%, as shares sank -0.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.31% upper at present.
During the last 5 trading sessions, JNJ rose by +1.64%, which changed the moving average for the period of 200-days by +13.08% in comparison to the 20-day moving average, which settled at $164.04. In addition, Johnson & Johnson saw 14.92% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JNJ starting from Decker Robert J, who sale 6,999 shares at the price of $165.88 back on Feb 25 ’25. After this action, Decker Robert J now owns 21,001 shares of Johnson & Johnson, valued at $1,160,994 using the latest closing price.
Decker Robert J, the Officer of Johnson & Johnson, proposed sale 6,999 shares at $165.88 during a trade that took place back on Feb 25 ’25, which means that Decker Robert J is holding shares at $1,161,010 based on the most recent closing price.
Stock Fundamentals for JNJ
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.69 for the gross margin
The net margin for Johnson & Johnson stands at 0.16. The total capital return value is set at 0.17. Equity return is now at value 20.06, with 8.09 for asset returns.
Based on Johnson & Johnson (JNJ), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at 0.66. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is 29.2.
Currently, EBITDA for the company is 24.78 billion with net debt to EBITDA at 0.51. When we switch over and look at the enterprise to sales, we see a ratio of 4.65. The receivables turnover for the company is 4.69for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.11.
Conclusion
To sum up, Johnson & Johnson (JNJ) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
